SurgePays Sold Business for $27.5 Million. Its Stock Fell 5%.

Something odd happened Wednesday. SurgePays, the tiny fintech-and-wireless company, announced it had completed the sale of its ClearLine point-of-sale engagement platform, its in-store retail media network, and a turnkey prepaid wireless business — for $27.5 million. And SURG, its stock, fell about 5%.

Not that mysteriously, once you read the small print. The $27.5 million was not paid in cash. It was paid in 25 million shares of newly designated Series D preferred stock of GPO Plus (OTCQB: GPOX), the buyer's parent. Each of those preferred shares converts, at the holder's election, one-for-one into GPO Plus common stock; it carries no dividend, no liquidation preference, and no voting rights. In other words, this is not really "preferred" stock at all. It is a non-voting slice of GPO Plus common equity wearing a nicer label.

Here is the thing about GPO Plus. It is an OTC penny stock that trades around two cents a share, with roughly 96 million shares out and a total market value of about $2 million. So 25 million shares of its stock are worth something in the neighborhood of half a million dollars on the open market, not $27.5 million. To make the arithmetic land at $27.5 million, you would have to value GPO Plus at $1.10 a share — roughly fifty times where the stock actually trades. The "sale" price is a number written into a contract; it is not what the market says the paper is worth.

So why book it at $27.5 million at all? Because SurgePays' balance sheet needed the number.

Why the number mattered

SurgePays was in genuine trouble. In March, Nasdaq told the company it was out of compliance with two continued-listing standards — the $35 million minimum market value of listed securities and the $1 minimum bid price — and the clock to fix the market-value shortfall ran out around September 14. A few weeks before that, SurgePays' stock had already collapsed 30% after hours when its second-quarter filing disclosed continued liquidity concerns.

The quarterly filing painted the picture. At June 30, 2026, SurgePays had about $1.95 million of cash on hand and had used $7.2 million of net cash in operations during the first half. Management expressed substantial doubt about the company's ability to continue as a going concern. And most relevant for a Nasdaq listing: total stockholders' equity was negative — a deficit of roughly $20.7 million. Nasdaq requires listed companies to hold at least $2.5 million of stockholders' equity to stay listed, and $5 million to get listed, and SurgePays was deep below both, not above them.

Enter the sale. Record $27.5 million of GPO Plus preferred stock as an asset, book the corresponding gain, and the balance sheet flips from a $20.7 million hole to positive equity above the listing thresholds. SurgePays says that after closing, its stockholders' equity now exceeds both the $2.5 million continued-listing requirement and the $5 million initial-listing requirement. The bid-price problem still has to be fixed — the company flagged a possible reverse split — but the equity shortfall, which no amount of operations was going to close before the September deadline, is gone on paper in a single day.

The backstop

SurgePays insists the $27.5 million is real, and it has a mechanism to point to: a put option. Under a put agreement with a fund called Emerald Shoals Targeted Opportunities Fund LP, SurgePays has the right, for three years plus 90 days after closing, to sell the preferred shares (or the common stock they convert into) to Emerald Shoals for $27.5 million in cash. That put, the company says, backstops the value of the deal.

In practice, the backstop is the weakest link in the machine, because everything depends on the counterparty's ability to actually pay. Emerald Shoals is a small, thinly documented fund of the sort that lives in SEC Form D filings; its one publicly recorded Form D raise, back in 2019, was for $400,000. It is also a financing counterparty with a prior history in SurgePays' ecosystem — a 2021 settlement between SurgePays and certain of its lenders contemplated a separate Emerald Shoals transaction for 5.5 million SurgePays shares. Whether a fund of roughly that footprint can produce $27.5 million in cash on demand — about six times the entire current market value of SURG itself — is the central open question of this whole deal. For agreeing to stand behind the value, GPO Plus handed Emerald Shoals a five-year warrant for a further 15 million GPO Plus shares at prices of five, fifteen, and twenty-five cents. Everybody who helped make the number real walks away holding more paper.

What it means for a shareholder

None of this means the operating business is dead, and it is worth walling the two things apart. SurgePays' core prepaid wireless and fintech line has genuinely been improving: second-quarter revenue rose 40.7% year over year to $16.2 million, and the company posted positive GAAP net income of $1.29 million to common stockholders. The stuff it just "sold" — the ClearLine engagement platform, the retail TV network, the turnkey MVNO — was peripheral to that core, and you could argue that moving it off the books simplifies the company. That is a real reading, and a fair one.

But here is the distinction the deal makes you draw: a company can simultaneously be improving its operating results and be running an accounting-engineered equity rescue. Those are two independent claims, and this transaction only makes sense as the second one. The question for a SurgePays shareholder is not whether revenue is growing. It is whether the "$27.5 million sale" is a $27.5 million event or a roughly half-million-dollar event dressed up to clear a listing threshold on the eve of a deadline.

If GPO Plus stock ever trades anywhere near $1.10, or if Emerald Shoals ever writes a real $27.5 million check, this was a clever trade and everyone should update. If not — if the preferred is eventually marked down to what 25 million shares of a two-cent stock are actually worth, or the put simply never gets funded — then the "$27.5 million sale" is best understood as SurgePays swapping real operating assets for a piece of a penny stock plus a promise from a thin fund to make everyone whole at a price the market says is fifty times too high.

The stock falling about 5% on the day of the big "sale" is the market's way of telling you which of those it believes.